Core Insights - BD (Becton, Dickinson and Company) has expanded its respiratory and STI diagnostics offerings in Europe with the IVDR certification of two new VIASURE assays for the BD MAX™ System, enhancing the detection capabilities for a wide range of pathogens [1][2] Group 1: Product Expansion - The newly certified assays include a respiratory virus detection kit that identifies multiple viruses such as SARS-CoV-2, flu (A and B), RSV, and others from a single nasopharyngeal swab, and an assay for herpes simplex viruses and Treponema pallidum from skin lesion swabs [5][6] - The BD MAX™ System can process up to 24 samples per run and provides results in approximately three hours with less than one minute of hands-on time per sample, supporting timely and reliable clinical decision-making [2][4] Group 2: Strategic Partnership - The partnership with Certest Biotec, which began in 2017, has been crucial for BD in expanding its diagnostic menu and is expected to lead to further innovative projects in the future [3][6] - Certest Biotec specializes in the development and commercialization of in vitro diagnostic medical devices, contributing to BD's broad portfolio in human diagnostics [5][6] Group 3: Company Overview - BD is one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery, with a commitment to enhancing safety and efficiency in healthcare [4] - The company employs over 70,000 individuals and collaborates with organizations worldwide to address significant global health challenges [4]